Magnolia Capital Advisors LLC Purchases Shares of 25,642 Zoetis Inc. (NYSE:ZTS)

Magnolia Capital Advisors LLC acquired a new position in Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, Holdings Channel reports. The firm acquired 25,642 shares of the company’s stock, valued at approximately $4,445,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its stake in shares of Zoetis by 31.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after acquiring an additional 3,244,074 shares during the last quarter. Sarasin & Partners LLP raised its holdings in Zoetis by 546.3% in the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after purchasing an additional 1,904,899 shares during the period. Swedbank AB purchased a new position in Zoetis during the first quarter valued at $210,815,000. Public Employees Retirement Association of Colorado bought a new stake in Zoetis during the fourth quarter valued at about $242,757,000. Finally, Marshall Wace LLP increased its position in Zoetis by 7,608.6% in the second quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock worth $144,874,000 after buying an additional 824,843 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on ZTS shares. Stifel Nicolaus lifted their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Piper Sandler lifted their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Zoetis presently has an average rating of “Buy” and a consensus price target of $220.38.

Zoetis Stock Down 0.0 %

Shares of ZTS stock opened at $194.81 on Friday. The stock has a market cap of $88.89 billion, a P/E ratio of 37.54, a PEG ratio of 2.97 and a beta of 0.88. The company’s fifty day simple moving average is $186.04 and its two-hundred day simple moving average is $174.79. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. During the same period in the prior year, the company earned $1.41 earnings per share. The firm’s revenue was up 8.3% on a year-over-year basis. Analysts predict that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.